Cancer vaccines in phase II/III clinical trials: State of the art and future perspectives

Current Cancer Drug Targets

Volumn 11, Issue 1, 2011, Pages 85-102

  Cecco, S ^a   Muraro, E ^b   Giacomin, E ^a   Martorelli, D ^b   Lazzarini, R ^a   Baldo, P ^c   Dolcetti, R ^b  

^a Pharmacy Unit   (Italy)

^b Advanced Immunotherapy Unit   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cancer; Clinical trials; Immunotherapy; Investigational drugs; Therapeutic vaccines; Tumor associated antigen

Indexed keywords

ADJUVANT; AMOLIMOGENE BEPIPLASMID; BELAGENPUMATUCEL L; BEVACIZUMAB; BIOVAXID; BLP 25; CANCER VACCINE; CDX 110; DC VAX; GSK 1572932; LUCANIX; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PEPTIDE VACCINE; PLASMID DNA; PROVENGE; RINDOPEPIMUT; STIMUVAX; TEMOZOLOMIDE; TERTOMOTIDE; TG 4010; UNCLASSIFIED DRUG; V 503; VIRUS VECTOR; VITESPEN; WART VIRUS VACCINE; ZYC 01A;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; COLORECTAL CANCER; CONSTIPATION; COUGHING; DENDRITIC CELL; DYSPNEA; FATIGUE; FEVER; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; KIDNEY CANCER; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; PAIN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RESPIRATORY TRACT DISEASE; SWELLING; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VAGINA BLEEDING; VAGINA CANCER; VULVA CANCER;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS;

EID: 78951495136     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911793743664     Document Type: Article

References (131)

1. Danaei, G.; Vander, H. S.; Lopez, A. D.; Murray, C. J.; Ezzati, M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005, 366, 1784-1793.
2. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411, 380-384.
3. Purcell, A. W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6, 404-414.
4. Fournier, P.; Schirrmacher, V. Randomized clinical studies of antitumor vaccination: state of the art in 2008. Expert. Rev. Vaccines 2009, 8, 51-66.
5. Itoh, K.; Yamada, A.; Mine, T.; Noguchi, M. Recent advances in cancer vaccines: an overview. Jpn. J. Clin. Oncol. 2009, 39, 73-80.
6. Chen, D. S.; Hsu, N. H.; Sung, J. L.; Hsu, T. C.; Hsu, S. T.; Kuo, Y. T.; Lo, K. J.; Shih, Y. T. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987, 257, 2597-2603.
7. Chen, X.; Chang, C. H.; Goldenberg, D. M. Novel strategies for improved cancer vaccines. Expert Rev. Vaccines 2009, 8, 567-576.
8. Mast, E. E.; Margolis, H. S.; Fiore, A. E.; Brink, E. W.; Goldstein, S. T.; Wang, S. A.; Moyer, L. A.; Bell, B. P.; Alter, M. J. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm. Rep. 2005, 54, 1-31.
9. Chang, M. H.; Chen, C. J.; Lai, M. S.; Hsu, H. M.; Wu, T. C.; Kong, M. S.; Liang, D. C.; Shau, W. Y.; Chen, D. S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 1997, 336, 1855-1859.
10. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond) 2006, 110, 525-541.
11. Lowy, D. R.; Schiller, J. T. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 2006, 116, 1167-1173.
12. Barr, E.; Sings, H. L. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008, 26, 6244-6257.
13. Greten, T. F.; Jaffee, E. M. Cancer vaccines. J. Clin. Oncol. 1999, 17, 1047-1060.
14. Kersh, G. J.; Allen, P. M. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med. 1996, 184, 1259-1268.
15. Kersh, G. J.; Allen, P. M. Essential flexibility in the T-cell recognition of antigen. Nature 1996, 380, 495-498.
16. Wolff, J. A.; Malone, R. W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P. L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247, 1465-1468.
17. Wu, T. C.; Guarnieri, F. G.; Staveley-O'Carroll, K. F.; Viscidi, R. P.; Levitsky, H. I.; Hedrick, L.; Cho, K. R.; August, J. T.; Pardoll, D. M. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA 1995, 92, 11671-11675.
18. Lin, K. Y.; Guarnieri, F. G.; Staveley-O'Carroll, K. F.; Levitsky, H. I.; August, J. T.; Pardoll, D. M.; Wu, T. C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996, 56, 21-26.
19. Borysiewicz, L. K.; Fiander, A.; Nimako, M.; Man, S.; Wilkinson, G. W.; Westmoreland, D.; Evans, A. S.; Adams, M.; Stacey, S. N.; Boursnell, M. E.; Rutherford, E.; Hickling, J. K.; Inglis, S. C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347, 1523-1527.
20. Zitvogel, L.; Mayordomo, J. I.; Tjandrawan, T.; DeLeo, A. B.; Clarke, M. R.; Lotze, M. T.; Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 1996, 183, 87-97.
21. Mayordomo, J. I.; Zorina, T.; Storkus, W. J.; Zitvogel, L.; Celluzzi, C.; Falo, L. D.; Melief, C. J.; Ildstad, S. T.; Kast, W. M.; DeLeo, A. B. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995, 1, 1297-1302.
22. Paglia, P.; Chiodoni, C.; Rodolfo, M.; Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 1996, 183, 317-322.
23. Gong, J.; Chen, D.; Kashiwaba, M.; Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 1997, 3, 558-561.
24. Specht, J. M.; Wang, G.; Do, M. T.; Lam, J. S.; Royal, R. E.; Reeves, M. E.; Rosenberg, S. A.; Hwu, P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 1997, 186, 1213-1221.
25. Song, W.; Kong, H. L.; Carpenter, H.; Torii, H.; Granstein, R.; Rafii, S.; Moore, M. A.; Crystal, R. G. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 1997, 186, 1247-1256.
26. Boczkowski, D.; Nair, S. K.; Snyder, D.; Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 1996, 184, 465-472.
27. Mailliard, R. B.; Wankowicz-Kalinska, A.; Cai, Q.; Wesa, A.; Hilkens, C. M.; Kapsenberg, M. L.; Kirkwood, J. M.; Storkus, W. J.; Kalinski, P. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004, 64, 5934-5937.
28. Lanzavecchia, A.; Sallusto, F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000, 290, 92-97.
29. Lee, J. J.; Foon, K. A.; Mailliard, R. B.; Muthuswamy, R.; Kalinski, P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J. Leukoc. Biol. 2008, 84, 319-325.
30. Gustafsson, K.; Ingelsten, M.; Bergqvist, L.; Nystrom, J.; Andersson, B.; Karlsson-Parra, A. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res. 2008, 68, 5965-5971.
31. Tacken, P. J.; de Vries, I. J.; Torensma, R.; Figdor, C. G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 2007, 7, 790-802.
32. Bonifaz, L. C.; Bonnyay, D. P.; Charalambous, A.; Darguste, D. I.; Fujii, S.; Soares, H.; Brimnes, M. K.; Moltedo, B.; Moran, T. M.; Steinman, R. M. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 2004, 199, 815-824.
33. Kretz-Rommel, A.; Qin, F.; Dakappagari, N.; Torensma, R.; Faas, S.; Wu, D.; Bowdish, K. S. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J. Immunother. 2007, 30, 715-726.
34. Yang, L.; Yang, H.; Rideout, K.; Cho, T.; Joo, K. I.; Ziegler, L.; Elliot, A.; Walls, A.; Yu, D.; Baltimore, D.; Wang, P. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 2008, 26, 326-334.
35. Lopes, L.; Dewannieux, M.; Gileadi, U.; Bailey, R.; Ikeda, Y.; Whittaker, C.; Collin, M. P.; Cerundolo, V.; Tomihari, M.; Ariizumi, K.; Collins, M. K. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J. Virol. 2008, 82, 86-95.
36. Kawakami, Y.; Eliyahu, S.; Delgado, C. H.; Robbins, P. F.; Sakaguchi, K.; Appella, E.; Yannelli, J. R.; Adema, G. J.; Miki, T.; Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 1994, 91, 6458-6462.
37. Van Der Bruggen, P.; Zhang, Y.; Chaux, P.; Stroobant, V.; Panichelli, C.; Schultz, E. S.; Chapiro, J.; Van Den Eynde, B. J.; Brasseur, F.; Boon, T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 2002, 188, 51-64.
38. Thomas, A. M.; Santarsiero, L. M.; Lutz, E. R.; Armstrong, T. D.; Chen, Y. C.; Huang, L. Q.; Laheru, D. A.; Goggins, M.; Hruban, R. H.; Jaffee, E. M. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 2004, 200, 297-306.
39. Copier, J.; Dalgleish, A. Overview of tumor cell-based vaccines. Int. Rev. Immunol. 2006, 25, 297-319.
40. Schijns, V. E. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 2000, 12, 456-463.
41. Christensen, D.; Korsholm, K. S.; Rosenkrands, I.; Lindenstrom, T.; Andersen, P.; Agger, E. M. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines 2007, 6, 785-796.
42. Lutsiak, M. E.; Robinson, D. R.; Coester, C.; Kwon, G. S.; Samuel, J. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 2002, 19, 1480-1487.
43. Maraskovsky, E.; Schnurr, M.; Wilson, N. S.; Robson, N. C.; Boyle, J.; Drane, D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunol. Cell Biol. 2009, 87, 371-376.
44. Habjanec, L.; Halassy, B.; Tomasic, J. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. Int. Immunopharmacol. 2008, 8, 717-724.
45. Bastos, R. G.; Borsuk, S.; Seixas, F. K.; Dellagostin, O. A. Recombinant Mycobacterium bovis BCG. Vaccine 2009, 27, 6495-6503.
46. Cheever, M. A. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 2008, 222, 357-368.
47. Pichichero, M. E. Improving vaccine delivery using novel adjuvant systems. Hum. Vaccin. 2008, 4, 262-270.
48. Harris, J. R.; Markl, J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron. 1999, 30, 597-623.
49. Allison, A. C. Squalene and squalane emulsions as adjuvants. Methods 1999, 19, 87-93.
50. Petrovsky, N.; Aguilar, J. C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 2004, 82, 488-496.
51. Gallucci, S.; Lolkema, M.; Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 1999, 5, 1249-1255.
52. Jones, K. S. Biomaterials as vaccine adjuvants. Biotechnol. Prog. 2008, 24, 807-814.
53. Tovey, M. G.; Lallemand, C. Adjuvant activity of cytokines. Methods Mol. Biol. 2010, 626, 287-309.
54. Schultz, N.; Oratz, R.; Chen, D.; Zeleniuch-Jacquotte, A.; Abeles, G.; Bystryn, J. C. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 1995, 13, 503-508.
55. Mocellin, S.; Rossi, C. R.; Nitti, D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp. Cell Res. 2004, 299, 267-278.
56. Nemunaitis, J.; Dillman, R. O.; Schwarzenberger, P. O.; Senzer, N.; Cunningham, C.; Cutler, J.; Tong, A.; Kumar, P.; Pappen, B.; Hamilton, C.; DeVol, E.; Maples, P. B.; Liu, L.; Chamberlin, T.; Shawler, D. L.; Fakhrai, H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 2006, 24, 4721-4730.
57. Fakhrai, H.; Mantil, J. C.; Liu, L.; Nicholson, G. L.; Murphy-Satter, C. S.; Ruppert, J.; Shawler, D. L. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 2006, 13, 1052-1060.
58. Butts, C.; Murray, N.; Maksymiuk, A.; Goss, G.; Marshall, E.; Soulieres, D.; Cormier, Y.; Ellis, P.; Price, A.; Sawhney, R.; Davis, M.; Mansi, J.; Smith, C.; Vergidis, D.; Ellis, P.; MacNeil, M.; Palmer, M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol 2005, 23, 6674-6681.
59. North, S. A.; Graham, K.; Bodnar, D.; Venner, P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J. Urol. 2006, 176, 91-95.
60. Brichard, V. G.; Lejeune, D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007, 25(Suppl. 2), B61-B71.
61. Tyagi, P.; Mirakhur, B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer 2009, 10, 371-374.
62. Available from http://www.gsk.com Media Release June 2007.
63. Lansdorp, P. M. Telomeres and disease. EMBO J. 2009, 28, 2532-40.
64. Available from http://www.pharmexa.com Press Release number 14/2008.
65. Bernhardt, S. L.; Gjertsen, M. K.; Trachsel, S.; Moller, M.; Eriksen, J. A.; Meo, M.; Buanes, T.; Gaudernack, G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br. J. Cancer 2006, 95, 1474-1482.
66. Brunsvig, P. F.; Aamdal, S.; Gjertsen, M. K.; Kvalheim, G.; Markowski-Grimsrud, C. J.; Sve, I.; Dyrhaug, M.; Trachsel, S.; Moller, M.; Eriksen, J. A.; Gaudernack, G. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 2006, 55, 1553-1564.
67. Tosti, G.; di, P. A.; Ferrucci, P. F.; Testori, A. HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future. Expert Rev. Vaccines 2009, 8, 1513-1526.
68. Testori, A.; Richards, J.; Whitman, E.; Mann, G. B.; Lutzky, J.; Camacho, L.; Parmiani, G.; Tosti, G.; Kirkwood, J. M.; Hoos, A.; Yuh, L.; Gupta, R.; Srivastava, P. K. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 2008, 26, 955-962.
69. Available from http://www.antigenics.com Press Release October 2009.
70. Available from http://www.ema.europa.eu November 2009 Doc. Ref. EMEA/763056/2009.
71. Limacher, J. M.; Acres, B. MUC1, a therapeutic target in oncology. Bull. Cancer 2007, 94, 253-257.
72. Acres, B.; Limacher, J. M. MUC1 as a target antigen for cancer immunotherapy. Expert Rev. Vaccines 2005, 4, 493-502.
73. Ramlau, R.; Quoix, E.; Rolski, J.; Pless, M.; Lena, H.; Levy, E.; Krzakowski, M.; Hess, D.; Tartour, E.; Chenard, M. P.; Limacher, J. M.; Bizouarne, N.; Acres, B.; Halluard, C.; Velu, T. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J. Thorac. Oncol. 2008, 3, 735-744.
74. Pujol, J. L.; Breton, J. L.; Gervais, R.; Rebattu, P.; Depierre, A.; Morere, J. F.; Milleron, B.; Debieuvre, D.; Castera, D.; Souquet, P. J.; Moro-Sibilot, D.; Lemarie, E.; Kessler, R.; Janicot, H.; Braun, D.; Spaeth, D.; Quantin, X.; Clary, C. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann. Oncol. 2005, 16, 602-610.
75. Hawkins, R. E.; Macdermott, C.; Shablak, A.; Hamer, C.; Thistlethwaite, F.; Drury, N. L.; Chikoti, P.; Shingler, W.; Naylor, S.; Harrop, R. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J. Immunother. 2009, 32, 424-429.
76. Harrop, R.; Drury, N.; Shingler, W.; Chikoti, P.; Redchenko, I.; Carroll, M. W.; Kingsman, S. M.; Naylor, S.; Melcher, A.; Nicholls, J.; Wassan, H.; Habib, N.; Anthoney, A. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res. 2007, 13, 4487-4494.
77. Harrop, R.; Drury, N.; Shingler, W.; Chikoti, P.; Redchenko, I.; Carroll, M. W.; Kingsman, S. M.; Naylor, S.; Griffiths, R.; Steven, N.; Hawkins, R. E. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 2008, 57, 977-986.
78. Tykodi, S. S.; Thompson, J. A. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert. Opin. Biol. Ther. 2008, 8, 1947-1953.
79. Harrop, R.; Connolly, N.; Redchenko, I.; Valle, J.; Saunders, M.; Ryan, M. G.; Myers, K. A.; Drury, N.; Kingsman, S. M.; Hawkins, R. E.; Carroll, M. W. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin. Cancer Res. 2006, 12, 3416-3424.
80. Amato, R. J.; Drury, N.; Naylor, S.; Jac, J.; Saxena, S.; Cao, A.; Hernandez-McClain, J.; Harrop, R. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J. Immunother. 2008, 31, 577-585.
81. Small, E. J.; Fratesi, P.; Reese, D. M.; Strang, G.; Laus, R.; Peshwa, M. V.; Valone, F. H. Immunotherapy of hormonerefractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000, 18, 3894-3903.
82. Higano, C. S.; Schellhammer, P. F.; Small, E. J.; Burch, P. A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M. W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in adcanced proste cancer. Cancer 2009, 15, 3670-3679.
83. Patel, P. H.; Kockler, D. R. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 2008, 42, 91-98.
84. Small, E. J.; Schellhammer, P. F.; Higano, C. S.; Redfern, C. H.; Nemunaitis, J. J.; Valone, F. H.; Verjee, S. S.; Jones, L. A.; Hershberg, R. M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006, 24, 3089-3094.
85. Available from http://www.dendreon.com Media Release April 2009.
86. Rini, B. I.; Weinberg, V.; Fong, L.; Conry, S.; Hershberg, R. M.; Small, E. J. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006, 107, 67-74.
87. Baccala, A.; Sercia, L.; Li, J.; Heston, W.; Zhou, M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007, 70, 385-390.
88. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999, 59, 3192-3198.
89. Mhawech-Fauceglia, P.; Zhang, S.; Terracciano, L.; Sauter, G.; Chadhuri, A.; Herrmann, F. R.; Penetrante, R. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007, 50, 472-483.
90. Elsasser-Beile, U.; Buhler, P.; Wolf, P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr. Drug Targets 2009, 10, 118-125.
91. Tjoa, B. A.; Simmons, S. J.; Bowes, V. A.; Ragde, H.; Rogers, M.; Elgamal, A.; Kenny, G. M.; Cobb, O. E.; Ireton, R. C.; Troychak, M. J.; Salgaller, M. L.; Boynton, A. L.; Murphy, G. P. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998, 36, 39-44.
92. Tjoa, B. A.; Lodge, P. A.; Salgaller, M. L.; Boynton, A. L.; Murphy, G. P. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J. Clin. 1999, 49, 117-28, 65.
93. Available from http://www.nwbio.com Media Release 21 October 2009.
94. Heimberger, A. B.; Sampson, J. H. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert. Opin. Biol. Ther. 2009, 9, 1087-1098.
95. Sampson, J. H.; Archer, G. E.; Mitchell, D. A.; Heimberger, A. B.; Herndon, J. E.; Lally-Goss, D.; McGehee-Norman, S.; Paolino, A.; Reardon, D. A.; Friedman, A. H.; Friedman, H. S.; Bigner, D. D. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 2009, 8, 2773-2779.
96. Kunwar, S.; Prados, M. D.; Chang, S. M.; Berger, M. S.; Lang, F. F.; Piepmeier, J. M.; Sampson, J. H.; Ram, Z.; Gutin, P. H.; Gibbons, R. D.; Aldape, K. D.; Croteau, D. J.; Sherman, J. W.; Puri, R. K. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 2007, 25, 837-844.
97. Alvarez-Salas, L. M. Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. Curr. Opin. Mol. Ther. 2008, 10, 622-628.
98. Klencke, B.; Matijevic, M.; Urban, R. G.; Lathey, J. L.; Hedley, M. L.; Berry, M.; Thatcher, J.; Weinberg, V.; Wilson, J.; Darragh, T.; Jay, N.; Da, C. M.; Palefsky, J. M. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. 2002, 8, 1028-1037.
99. Sheets, E. E.; Urban, R. G.; Crum, C. P.; Hedley, M. L.; Politch, J. A.; Gold, M. A.; Muderspach, L. I.; Cole, G. A.; Crowley-Nowick, P. A. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol. 2003, 188, 916-926.
100. Garcia, F.; Petry, K. U.; Muderspach, L.; Gold, M. A.; Braly, P.; Crum, C. P.; Magill, M.; Silverman, M.; Urban, R. G.; Hedley, M. L.; Beach, K. J. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 2004, 103, 317-326.
101. de Gruijl, T. D.; Curiel, D. T. Cancer vaccine strategies get bigger and better. Nat. Med. 1999, 5, 1124-1125.
102. Neelapu, S. S.; Kwak, L. W.; Kobrin, C. B.; Reynolds, C. W.; Janik, J. E.; Dunleavy, K.; White, T.; Harvey, L.; Pennington, R.; Stetler-Stevenson, M.; Jaffe, E. S.; Steinberg, S. M.; Gress, R.; Hakim, F.; Wilson, W. H. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 2005, 11, 986-991.
103. Available from http://www.accentia.net/science_biovaxid.php
104. [104] Rezvani, K. PR1 vaccination in myeloid malignancies. Expert Rev. Vaccines 2008, 7, 867-875.
105. Emens, L. A.; Jaffee, E. M. Cancer vaccines: an old idea comes of age. Cancer Biol. Ther. 2003, 2, S161-S168.
106. Emens, L. A.; Reilly, R. T.; Jaffee, E. M. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr. Relat. Cancer 2005, 12, 1-17.
107. Espinoza-Delgado, I. Cancer vaccines. Oncologist 2002, 7(Suppl. 3), 20-33.
108. Berinstein, N. L. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Ann. N. Y. Acad. Sci. 2009, 1174, 107-117.
109. Bodey, B.; Bodey, B., Jr.; Siegel, S. E.; Kaiser, H. E. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 2000, 20, 2665-2676.
110. Lee, K. H.; Panelli, M. C.; Kim, C. J.; Riker, A. I.; Bettinotti, M. P.; Roden, M. M.; Fetsch, P.; Abati, A.; Rosenberg, S. A.; Marincola, F. M. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 1998, 161, 4183-4194.
111. Keilholz, U.; Weber, J.; Finke, J. H.; Gabrilovich, D. I.; Kast, W. M.; Disis, M. L.; Kirkwood, J. M.; Scheibenbogen, C.; Schlom, J.; Maino, V. C.; Lyerly, H. K.; Lee, P. P.; Storkus, W.; Marincola, F.; Worobec, A.; Atkins, M. B. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 2002, 25, 97-138.
112. Wang, Q.; Ornstein, M.; Kaufman, H. L. Imaging the immune response to monitor tumor immunotherapy. Expert Rev. Vaccines 2009, 8, 1427-1437.
113. Wang, E.; Miller, L. D.; Ohnmacht, G. A.; Mocellin, S.; Perez-Diez, A.; Petersen, D.; Zhao, Y.; Simon, R.; Powell, J. I.; Asaki, E.; Alexander, H. R.; Duray, P. H.; Herlyn, M.; Restifo, N. P.; Liu, E. T.; Rosenberg, S. A.; Marincola, F. M. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002, 62, 3581-3586.
114. Parmiani, G.; De, F. A.; Novellino, L.; Castelli, C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 2007, 178, 1975-1979.
115. Pilla, L.; Rivoltini, L.; Patuzzo, R.; Marrari, A.; Valdagni, R.; Parmiani, G. Multipeptide vaccination in cancer patients. Expert Opin. Biol. Ther. 2009, 9, 1043-1055.
116. Iero, M.; Filipazzi, P.; Castelli, C.; Belli, F.; Valdagni, R.; Parmiani, G.; Patuzzo, R.; Santinami, M.; Rivoltini, L. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Cancer Immunol. Immunother. 2009, 58, 1159-1167.
117. Tine, J. A.; Firat, H.; Payne, A.; Russo, G.; Davis, S. W.; Tartaglia, J.; Lemonnier, F. A.; Demoyen, P. L.; Moingeon, P. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes. Vaccine 2005, 23, 1085-1091.
118. Melief, C. J.; van der Burg, S. H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 2008, 8, 351-360.
119. Bettahi, I.; Dasgupta, G.; Renaudet, O.; Chentoufi, A. A.; Zhang, X.; Carpenter, D.; Yoon, S.; Dumy, P.; BenMohamed, L. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol. Immunother. 2009, 58, 187-200.
120. Baxevanis, C. N.; Perez, S. A.; Papamichail, M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother. 2009, 58, 317-324.
121. Egen, J. G.; Kuhns, M. S.; Allison, J. P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002, 3, 611-618.
122. Maker, A. V.; Phan, G. Q.; Attia, P.; Yang, J. C.; Sherry, R. M.; Topalian, S. L.; Kammula, U. S.; Royal, R. E.; Haworth, L. R.; Levy, C.; Kleiner, D.; Mavroukakis, S. A.; Yellin, M.; Rosenberg, S. A. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 2005, 12, 1005-1016.
123. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8, 59-73.
124. Barrett, J.; Le Blanc, K. Cancer chemotherapy and immune regulation. Am. J. Immunol. 2009, 5, 8-16.
125. Chan, O. T.; Yang, L. X. The immunological effects of taxanes. Cancer Immunol. Immunother. 2000, 49, 181-185.
126. Ibrahim, N. K.; Murray, J. L. Clinical development of the STn-KLH vaccine (Theratope). Clin. Breast Cancer 2003, 3(Suppl. 4), S139-S143.
127. Miles, D. W.; Towlson, K. E.; Graham, R.; Reddish, M.; Longenecker, B. M.; Taylor-Papadimitriou, J.; Rubens, R. D. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 1996, 74, 1292-1296.
128. Emens, L. A.; Machiels, J. P.; Reilly, R. T.; Jaffee, E. M. Chemotherapy: friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. 2001, 3, 77-84.
129. Serrano, A.; Tanzarella, S.; Lionello, I.; Mendez, R.; Traversari, C.; Ruiz-Cabello, F.; Garrido, F. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int. J. Cancer 2001, 94, 243-251.
130. Dudley, M. E.; Wunderlich, J. R.; Robbins, P. F.; Yang, J. C.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Sherry, R.; Restifo, N. P.; Hubicki, A. M.; Robinson, M. R.; Raffeld, M.; Duray, P.; Seipp, C. A.; Rogers-Freezer, L.; Morton, K. E.; Mavroukakis, S. A.; White, D. E.; Rosenberg, S. A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298, 850-854.
131. Yee, C.; Thompson, J. A.; Byrd, D.; Riddell, S. R.; Roche, P.; Celis, E.; Greenberg, P. D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 2002, 99, 16168-16173.